

Systematic discovery of drug interaction mechanisms

杨倩 生物信息学 2018/1/12





Content

- Abstract
- Materials
- Methods
- Results & Discussion





Abstract

- To uncover the causes of drug interactions
- We found that drug interactions highly robust to genetic perturbation
- Small molecule adjuvants targeting these functions synthetically reshape drug interactions in predictable ways.





Materials

• Escherichia coli strains with kanamycin resistance marker

• Low-copy-number plasmid (pUA66)

Antibiotics from Sigma-Aldrich

Adjuvants







Materials

Table 1. Antibiotics used in this study.

Table 1. Antibiotics used in this study.			
Abbreviation	Drug	Mode of action (known target)	Concentration
CHL	Chloramphenicol	Protein synthesis (50S ribosome subunit)	1 μg/ml
CPR	Ciprofloxacin	DNA replication (gyrase)	4 ng/ml
MEC	Mecillinam	Cell wall (Penicillin Binding Protein)	38 ng/ml
NIT	Nitrofurantoin	Multiple mechanisms	2 μg/ml
TET	Tetracycline	Protein synthesis (30S ribosome subunit)	150 ng/ml
TMP	Trimethoprim	Folic acid synthesis (DHFR)	80 ng/ml









Methods




Plate containing 200µl medium.PRE: plates were shaken on a magnetic shaker at 900 rpm for 20 s. Cultures were inoculated using a replicator transferring \sim 0.2 µl from aovernight culture kept at -80° C with 15% glycerol.The plates were incubated in an automated incubator (Liconic Storex) kept at 30° C, > 95% humidity, and shaken at 720 rpm,for \sim 20h.





Methods

- Growth rate measurements
- Two-drug response surfaces
- Expected growth rate in drug combinations
- Gene ontology enrichment analysis





Methods-Growth rate measurements

• The growth rate in exponential phase was quantified from the OD increase over time by a linear fit of log(OD) in the range 0.022 < OD < 0.22

For the representation of two-dimensional response surfaces, we used the optical density 12 h after inoculation instead of the growth rate because this quantity was slightly more reproducible and yielded smoother response surfaces; this representation does not affect any of the conclusions on drug interaction changes






Methods-Two-drug response surfaces

$$c = c_{\max} \frac{x^3 + ax}{1 + a}$$

- c_{max} was the highest concentration used,
- x was linearly spaced from 0 to 1 with 8, 12, or 24 stepsdepending on the experiment,
- a = 1/3







Methods-Expected growth rate in drug combinations

$$r^i(a) = \frac{g^i(a)}{g^i(0)}$$

 $r^i(a)=rac{g^i(a)}{g^i(0)}$ gi(a) denote the growth rate of mutant i in the presence of drug A

gi(0) denote the growth rate of mutant i in the absence of drug A

$$r^{\text{WT}}(a_{\text{eff}}^i) = r^i(a)$$

ai_{eff} —— effective concentration

$$\alpha^{i} = a_{\text{eff}}^{i}/a$$

$$\beta^{i} = b_{\text{eff}}^{i}/b$$

$$\gamma^{i} = g^{i}(0)/g^{\text{WT}}$$

$$I^{\text{WT}}(a,b) = \frac{r^{\text{WT}}(a,b)}{r^{\text{WT}}(a)r^{\text{WT}}(b)}$$

$$g^i(a,b) = g^i(0) \cdot r^i(a) \cdot r^i(b) \cdot I^{\text{WT}}(a^i_{\text{eff}},b^i_{\text{eff}})$$

this equation formalizes the assumption that the interaction coefficient is a universal invariant and, for all mutants, is the same as in the WT at the effective drug concentrations.



Methods-Gene ontology enrichment analysis

• 分子生物学上的功能


• 生物学途径

• 在细胞中的组件作用






drug interactions highly robust to genetic perturbation











drug interactions affect by rare genetic perturbation



drug interactions highly robust to the most of genetic perturbation








faithfully followed robustness






chloramphenicol—nitrofurantoin suppression was weakened or entirely removed in most mutants affecting this interaction




chloramphenicol trimethoprim antagonism was often amplified to suppression








difference between WT and mutant strains on drug interaction








Polysaccharide synthesis



ATP synthesis



suppressive—additive

antagonistic→suppressive





- 结论
- 作者得出一个普遍规律:大多数药物的互做对基因扰动是稳定的。少数基因突变会改变药物互做反应。在多糖合成和ATP合成中可以通过影响非靶标途径,改变药物互作机制。





- 创新点
- 作者用系统的方法,从药物分子在生物学上的功能出发,研究了结合了其生物学途径、在细胞中的组件作用,最终发现规律。这种以小见大,是他们的一种新思路。





- 启发
- 1.作者做研究的全局性值得我们学习,因小见大,不被微观研究局限;
- 2.作者欲将他发现的规律,像物理规律一般,能有普适性。我们在研究中,也不要仅停留在表象,要有一颗深入研究的心,找到事物本质联系。





- 改进
- 作者研究了药物互做机制,如何从拮抗转 化到抑制,其实可以进一步研究,看能不 能找到一些佐剂,再转化到加成或者协作。
- 作者没有明确讲述所使用的基因突变的类型,不同位置的突变可能对药物互做的影响不同,没有做分类说明,这个可以进行分类,排除突变造成的差异影响对药物互作影响的判断。





•Thank you

